News - BCL2 fusion - LARVOL VERI

Lineage Switch from Therapy-Related B Cell Acute Lymphoblastic Leukemia to Pure Erythroid Leukemia Following CD20-Directed Immunotherapy: A Mechanism for Immune Escape? (AMP 2024)

Six weeks later, while receiving the CD20-directed immunotherapies glofitamab and obinutuzumab, another bone marrow biopsy revealed eradication of the B-ALL and new involvement by pure erythroid leukemia (PEL). This patient's B-ALL lacked an IGH::BCL2 fusion resulting from t(14; 18), suggesting it did not arise through transformation of his prior FL/DLBCL. Instead, the B-ALL was likely caused by his extensive exposure to genotoxic chemotherapy drugs – including alkylating agents – for his preceding lymphomas. The shared cytogenetic and molecular features between this patient's B-ALL and PEL imply they are clonally related.

1 month ago

IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • KMT2A (Lysine Methyltransferase 2A)

TP53 mutation • KMT2A rearrangement • MLL rearrangement • BCL2 fusion

TruSight Myeloid Sequencing Panel

Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)

2ms

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR. (PubMed, Methods Mol Biol)

However, it should be noted that MRD diagnostics for clinical treatment protocols has to be accompanied by regular international quality control rounds to ensure the reproducibility and reliability of the MRD results. This is available by the EuroMRD network ( https://euromrd.org ), a subgroup of ESHLO ( https://eslho.org ).

2 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus)

Chr t(11;14) • Chr t(11;14)(q13;q32) • BCL2 fusion

8ms

Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively. (PubMed, Leuk Lymphoma)

The former is considered to be mediated by VDJ-recombination, while the latter by the class switch recombination process. There were no particular features in FL or CLL cases with IGH::5' BCL2 breakpoints compared with those with t(14;18)(q32;q21)/IGH::BCL2 involving the 3' breakpoint cluster regions.

8 months ago

Journal

BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2)

BCL2 fusion

over1year

Diagnostic clues of BCL2-negative, faint, or controversial follicular lymphomas: A study of 103 cases. (PubMed, Hum Pathol)

In conclusion, morphological examination of the distribution of CD20-and/or CD10-positive cells and the presence of diffuse area could be used to diagnose FL in most cases. The majority of the remaining FL cases could be diagnosed using other BCL2 clones and clonality analyses.

over 1 year ago

Retrospective data • Journal

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)

CD20 positive • BCL2 positive • BCL2 fusion

over1year

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. (PubMed, Signal Transduct Target Ther)

Genetic subtype-guided targeted agents achieved encouraging clinical response when combined with immunochemotherapy. Collectively, LymphPlex provided high efficacy and feasibility, representing a step forward to the mechanism-based targeted therapy in DLBCL.

over 1 year ago

Journal • IO biomarker

TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • B2M (Beta-2-microglobulin) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD70 (CD70 Molecule) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • GNA13 (G Protein Subunit Alpha 13) • IRF8 (Interferon Regulatory Factor 8) • PIM1 (Pim-1 Proto-Oncogene) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CCND3 (Cyclin D3) • IRF4 (Interferon regulatory factor 4) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • BTG2 (BTG Anti-Proliferation Factor 2) • DDX3X (DEAD-Box Helicase 3 X-Linked) • TBL1XR1 (TBL1X Receptor 1) • ZFP36 (ZFP36 Ring Finger Protein)

TP53 mutation • ARID1A mutation • NOTCH1 mutation • EZH2 mutation • MYC expression • MYC rearrangement • STAT3 mutation • GNA13 mutation • PRDM1 mutation • IRF8 mutation • BCL2 fusion • BCL6 fusion

almost2years

Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Biological Data. (PubMed, Cancers (Basel))

In-situ follicular B-cell neoplasm, pediatric-type FL, duodenal-type FL and primary cutaneous follicle center lymphoma are categorized as discrete entities. In addition, novel findings concerning underlying biological mechanisms in the pathogenesis of early and systemic follicular lymphoma will be presented.

almost 2 years ago

Review • Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • TNFRSF14 (TNF Receptor Superfamily Member 14) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • FCER2 (Fc Fragment Of IgE Receptor II)

BCL2 expression • TNFRSF14 mutation • BCL2 fusion

2years

IGH/BCL2 Status Better Predicts Clinico-Pathological Behavior in Primary Splenic Follicular Lymphoma than Histological Grade and Other Molecular Markers. (PubMed, Clin Pathol)

This profile is associated with less aggressive clinical behavior even when histopathology represents a high-grade pattern. In such cases splenectomy alone is adequate for localized disease when negative for IGH/BCL2 fusion regardless of histological grade.

2 years ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • ITGAX (Integrin Subunit Alpha X)

BCL2 fusion

2years

EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16. (PubMed, Leuk Lymphoma)

These results suggest that DZNep may have potential as a novel therapeutic agent for DFLBL therapy. This agent may serve as a novel molecular agent to be applied to GCB DLBCL.

2 years ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2)

NOTCH1 mutation • EZH2 mutation • MYD88 L265P • NOTCH2 mutation • BCL2 fusion • BCL6 fusion

over2years

Follicular Lymphoma of the Oral Mucosa: Study of 5 Cases and Review of Literature (CAP 2022)

Follicular lymphoma is a rare extranodal NHL of the oral cavity, compared with variants of NHL. Although FLs share similar morphologic and immunohistochemical features, they can reveal some molecular and genetic differences.

over 2 years ago

Clinical • Review

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SPN (Sialophorin)

BCL6 rearrangement • BCL2 rearrangement • BCL2 fusion

over2years

Follicular Lymphoma of the Oral Mucosa: Study of 5 Cases and Review of Literature (CAP 2022)

over 2 years ago

Clinical • Review

BCL6 rearrangement • BCL2 rearrangement • BCL2 fusion

over3years

[VIRTUAL] Unusual Presentation of Cyclin D1 Expression in a Case of Follicular Lymphoma That Transformed to an Epstein-Barr Virus (EBV)–Positive Diffuse Large B-Cell Lymphoma (CAP 2021)

The presence of trisomy 11 in a subset of cells may explain the partial cyclin D1 overexpression observed. To avoid an incorrect diagnosis when cyclin D1 expression is observed in part of the lymphoma cells, FISH analysis is critical.

over 3 years ago

Clinical • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)

CD20 positive • CCND1 overexpression • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement • BCL2 fusion

over3years

[VIRTUAL] Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification. (ASCO 2021)

Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax . NGS profiling led to a targeted therapy with a clinical benefit rate of 12% in this cohort . NGS profiling led to a change in diagnosis in 5% of this cohort . Multi-institutional collaborations to track outcomes of matched therapy would help determine the utility of therapies in rare cancers and unusual alterations.

over 3 years ago

Clinical • Next-generation sequencing • Tumor Mutational Burden • IO biomarker

TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TPM4 (Tropomyosin 4)

TMB-H • NTRK3 fusion • MET amplification • IL7R-BCL2 fusion • PML-JAK1 fusion • TPM4-NTRK3 fusion • BCL2 fusion

Venclexta (venetoclax) • Xalkori (crizotinib) • Vitrakvi (larotrectinib) • Jakafi (ruxolitinib)

over3years

Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer. (PubMed, Int J Hematol)

Malignant lymphoma developing during anti-PD-1 antibody treatment is extremely rare. Relapsed FL was diagnosed by submandibular gland biopsy four months after restarting PEM and she achieved a second CMR after rituximab-containing chemotherapy. We describe the first case of newly diagnosed FL during PEM treatment.

over 3 years ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • IL2 (Interleukin 2)

BCL2 fusion

Keytruda (pembrolizumab) • Rituxan (rituximab)